Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …

Background ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal
cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed …

Abstract Background HER2 (ERBB2) amplification is present in 5-10% of patients (pts) with
KRAS and NRAS (RAS) WT mCRC. Tucatinib (Seattle Genetics, Bothell, WA) is a potent …

Background HER2 is an actionable target in metastatic colorectal cancer. We assessed the
activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2 …

Background HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as
demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer …

Background Therapies targeting HER2 have improved clinical outcomes in HER2-positive
breast and gastric cancers, and are emerging as potential treatments for HER2-positive …

Background The anti-EGFR monoclonal antibodies panitumumab and cetuximab are
effective in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic …

Background HER2 amplification is detected in 3% of patients with colorectal cancer (CRC),
making tumors in the metastatic setting vulnerable to double pharmacological HER2 …

Background HER2 amplification has been identified in 2–3% of patients with colorectal
cancer, although there are currently no approved HER2-targeted therapies for colorectal …

Background Integrins are involved in tumour progression and metastasis, and differentially
expressed on colorectal cancer (CRC) cells. Abituzumab (EMD 525797), a humanised …